Author Affiliations: Department of Clinical Nursing, Fourth Military Medical University, Xi’an, China (email@example.com).
To the Editor: Dr Peralta and colleagues1 reported that “adding cystatin C to creatinine and albuminuria for risk prediction can more accurately reclassify persons and can distinguish important prognostic differences, namely a 3-fold risk of death and 4-fold risk of end-stage renal disease.” However, they did not explain why they chose cystatin C as a biomarker for CKD diagnosis or assess the accuracy of applying it.
Zhao L, Wang W, Cui Y. Biomarkers for Detecting and Risk-Stratifying Chronic Kidney Disease. JAMA. 2011;306(6):611–612. doi:10.1001/jama.2011.1111
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: